The NeurATRIS initiative aims at creating a specific Translational Research Infrastructure for Biotherapies and Neurosciences.
This project has been funded by the “ Investissements d’Avenir -Infrastructure en Biologie et Santé “ call (Total funding : ¤ 28 million) and is coordinated by the Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA).
NEURATRIS aims to strengthen the infrastructure for translational research of the Institute for Translational Neuroscience of Paris IHU-A-ICM, with a main focus in the field of biotherapy in neuroscience.
NEURATRIS is also composed of different other partners that provide skills particularly in neuro-imaging, preclinical pharmacology and biotherapy.
The consortium will take advantage of the resources of the different partner’s preclinical and clinical platforms which have already demonstrated their know-how and performance in translational research and are now looking for more possibilities of increasing their services, namely :
- The IHU-A-ICM gathering a wealth of scientific, technological and therapeutic expertise’s in drug-based therapies of a large panel of brain diseases,
- The three major technological research centers of CEA (MIRCen, Neurospin, SHFJ), making this an international hub for research and innovation in imaging and biomedical technologies,
- Two other medium size clinical centers (Henri Mondor-UPEC and Neurosciences Bicêtre -Paris Sud) with a strong expertise in biotherapies for neurodegenerative diseases, psychiatry and in pediatric neurology,
- The Biotherapies Institute for Rare Diseases (BIRD), a R&D Centre that promotes the development of innovative therapies based on gene and cell therapies for various applications and clinical indications.
Extranodal Partners, UMR 676 Inserm-Paris 7 and UMR 663 Inserm-Paris 5 will provide expertise for methodological development in the emerging domain of the developing brain
The Infrastructure will strengthen basic research in neuroscience including a better understanding of the mechanisms of nervous system and will fuel future developments based on clinical biotherapy. This project will develop new approaches to diagnosis, care diseases of the nervous system that have an impact on both the health and well-being of citizens, but also in terms of public health.
The different complementary “nodal” expertises will form a unique and networked platforms dedicated to neurosciences that will enable selected external projects to “travel” between the different preclinical and clinical research centres depending on their stage of advancement on the one hand, and on the chosen therapeutic option on the other.
The NeurATRIS research teams will also conduct Technology Research and Development projects through 5 WorkPackages (WP) which are implemented to specifically address scientific, technological and medical challenges faced by the translational research in neurology. For each scientific WP, global thinking was conducted by research teams associated to nodes, to identify major scientific and technological obstacles to overcome, in order to strengthen the platforms.
Each workpackage is led by two scientific coordinators (one for the pre-clinical applications and one for the clinical applications).
NeurATRIS is the French partner in the European Advanced Translational Research Infrastructure in Medicine (2006 ESFRI roadmap) - EATRIS, and will allow France to be an important player in this field.
By coupling the “Institut de Neurosciences Translationnelles de Paris” (IHU-A-ICM) and the skills of other key partners expert in biotherapies and neurodevelopmental disorders, NeurATRIS will become a strong national entity able to join EATRIS as the sole European Translational
Research Infrastructure dedicated to Neurosciences.
NeurATRIS will also benefit from new imaging developments from France FLI Imaging and clinical developments from F-CRIN Infrastructures, as NeurATRIS projects may need Services from their platforms.
The NeurATRIS Research Infrastructure will trigger strong and durable public/private partnerships and answer to three major and complementary issues for industrial competitiveness and health by :
- developing specific lines of translational research and know-hows in Neuroscience aiming at discovering and qualifying at the preclinical and clinical level new therapeutic solutions for a multiplicity of brain diseases including neurodevelopmental and psychiatric disorders,
- overcoming the fragmented nature of science in bringing together various specialists of cell, gene and drug-based technologies enabling cross-functional fusion of skills and expertise in a single structure, as an efficient mean to perform proof of principle and proof of concept studies,
- offering an easy access to state-of-the-art platforms along with highly trained personnel to academic, clinical and industrial sectors.
If you are from academia or industry, you want to develop an imaging project or using the latest tools in imaging, and you think the infrastructure NeurATRIS can help you implement your project, feel free to contact us by clicking HERE.